
ImmunityBio, Inc. (NASDAQ:IBRX) shares are trading higher Tuesday after the company announced its chemotherapy-free combination showed 100% disease control results and is planning a Phase 2 trial.
What To Know: ImmunityBio reported early findings from five patients with recurrent glioblastoma, a deadly form of brain cancer, who were treated with its immune-boosting regimen combining ANKTIVA, natural killer cell therapy and the Optune Gio device. All five patients showed disease control, including two with near-complete responses and three with either partial response or stable disease.